TY - JOUR
T1 - Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support
T2 - A multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi)
AU - Tarella, C.
AU - Zanni, M.
AU - Di Nicola, M.
AU - Patti, C.
AU - Calvi, R.
AU - Pescarollo, A.
AU - Zoli, V.
AU - Fornari, A.
AU - Novero, D.
AU - Cabras, A.
AU - Stella, M.
AU - Comino, A.
AU - Remotti, D.
AU - Ponzoni, M.
AU - Caracciolo, D.
AU - Ladetto, M.
AU - Magni, M.
AU - Devizzi, L.
AU - Rosato, R.
AU - Boccadoro, M.
AU - Bregni, M.
AU - Corradini, P.
AU - Gallamini, A.
AU - Majolino, I.
AU - Mirto, S.
AU - Gianni, A. M.
PY - 2007/8
Y1 - 2007/8
N2 - A prospective multicenter program was performed to evaluate the combination of rituximab and high-dose (hd) sequential chemotherapy delivered with multiple autologous peripheral blood progenitor cell (PBPC) support (R-HDS-maps regimen) in previously untreated patients with diffuse large B-cell lymphoma (DLB-CL) and age-adjusted International Prognostic Score (aaIPI) score 2-3. R-HDS-maps includes: (i) three APO courses; (ii) sequential administration of hd-cyclophosphamide (CY), hd-Ara-C, both supplemented with rituximab, hd-etoposide/cisplatin, PBPC harvests, following hd-CY and hd-Ara-C; (iii) hd-mitoxantrone (hd-Mito)/L-Pam + 2 further rituximab doses; (iv) involved-field radiotherapy. PBPC rescue was scheduled following Ara-C, etoposide/cisplatin and Mito/L-Pam. Between 1999 and 2004, 112 consecutive patients aged
AB - A prospective multicenter program was performed to evaluate the combination of rituximab and high-dose (hd) sequential chemotherapy delivered with multiple autologous peripheral blood progenitor cell (PBPC) support (R-HDS-maps regimen) in previously untreated patients with diffuse large B-cell lymphoma (DLB-CL) and age-adjusted International Prognostic Score (aaIPI) score 2-3. R-HDS-maps includes: (i) three APO courses; (ii) sequential administration of hd-cyclophosphamide (CY), hd-Ara-C, both supplemented with rituximab, hd-etoposide/cisplatin, PBPC harvests, following hd-CY and hd-Ara-C; (iii) hd-mitoxantrone (hd-Mito)/L-Pam + 2 further rituximab doses; (iv) involved-field radiotherapy. PBPC rescue was scheduled following Ara-C, etoposide/cisplatin and Mito/L-Pam. Between 1999 and 2004, 112 consecutive patients aged
UR - http://www.scopus.com/inward/record.url?scp=34447626101&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34447626101&partnerID=8YFLogxK
U2 - 10.1038/sj.leu.2404781
DO - 10.1038/sj.leu.2404781
M3 - Article
C2 - 17554382
AN - SCOPUS:34447626101
VL - 21
SP - 1802
EP - 1811
JO - Leukemia
JF - Leukemia
SN - 0887-6924
IS - 8
ER -